Meloxicam: Selective COX-2 inhibition in clinical practice
- 1 June 1997
- journal article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 26, 21-27
- https://doi.org/10.1016/s0049-0172(97)80049-2
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Selective inhibition of human cyclo-oxygenase-2 by meloxicamInflammopharmacology, 1996
- Safety of Meloxicam: A Global Analysis of Clinical TrialsRheumatology, 1996
- A 4-Week, Double-Blind, Parallel-Group Study to Compare the Gastrointestinal Effects of Meloxicam 7.5 mg, Meloxicam 15 mg, Piroxicam 20 mg and Placebo by Means of Faecal Blood Loss, Endoscopy and Symptom Evaluation in Healthy VolunteersRheumatology, 1996
- Meloxicam in Osteoarthritis: A 6-Month, Double-Blind Comparison with Diclofenac SodiumRheumatology, 1996
- A Six-Month Double-Blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid ArthritisRheumatology, 1996
- Meloxican: Influence on arachidonic acid metabolism: Part 1. In vitro findingsBiochemical Pharmacology, 1996
- Distinct isoforms (COX‐1 and COX‐2) of cyclooxygenase: possible physiological and therapeutic implicationsFundamental & Clinical Pharmacology, 1996
- Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (LODINE)Inflammopharmacology, 1995
- Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1European Journal of Pharmacology, 1995
- Safety evaluation of nabumetone in United States clinical trialsThe American Journal of Medicine, 1987